Before you acquire a pharmacy, verify PBM contracts, prescription file health, DEA compliance, and staff licensing to avoid costly post-close surprises.
Acquiring an independent pharmacy involves far more complexity than a standard business purchase. Beyond financial statements, buyers must evaluate prescription file integrity, PBM reimbursement exposure, DEA and state board transferability, and staff licensing status. This checklist walks through the five critical due diligence categories every pharmacy buyer must complete before signing a purchase agreement.
Assess true pharmacy profitability after adjusting for owner compensation, DIR fees, and PBM reimbursement trends across all payer categories.
Review 3 years of tax returns, P&L statements, and monthly revenue reports segmented by payer and drug category.
Reveals true revenue mix and identifies dangerous concentration in low-margin payers or generics.
Red flag: Revenue is dominated by one PBM network or payer accounting for more than 40% of total prescription sales.
Obtain a trailing 12-month DIR fee reconciliation report from each PBM relationship.
DIR fees are retroactively clawed back and can reduce net reimbursement by 5–15%, distorting EBITDA.
Red flag: Seller cannot produce DIR fee reports or has unresolved disputed clawbacks with a PBM.
Recalculate adjusted EBITDA by normalizing owner compensation, perks, and non-recurring expenses.
Owner-pharmacists frequently understate compensation, inflating apparent profitability for buyers.
Red flag: Adjusted EBITDA margin falls below 6% after normalization, signaling structural profitability issues.
Analyze accounts receivable aging from third-party payers, Medicare Part D, and Medicaid.
Aged receivables over 90 days from government payers may indicate billing disputes or audit exposure.
Red flag: More than 15% of AR is over 90 days old, especially from Medicare or Medicaid payers.
Evaluate active patient volume, refill rates, and prescription file transferability — the core drivers of pharmacy enterprise value.
Request a prescription file report showing active patient count, 30-day refill rates, and top drug categories.
Active refill volume is the primary value driver; declining counts signal patient attrition risk.
Red flag: Active patient count or 30-day refill rates have declined more than 10% over the trailing 24 months.
Confirm the prescription file is owned by the business entity and not personally by the pharmacist-owner.
Personally held prescription files may not transfer with an asset purchase, destroying core business value.
Red flag: Seller claims patients follow the owner personally with no documented business-level patient records.
Assess patient concentration risk by reviewing the top 50 patients by annual prescription spend.
Excessive concentration in a few high-spend patients creates attrition risk that can materially reduce revenue.
Red flag: Top 10 patients represent more than 20% of total annual prescription revenue.
Review any long-term care, hospice, or institutional facility contracts included in the prescription volume.
Recurring institutional contracts are highly valuable but may require renegotiation or approval upon ownership change.
Red flag: Institutional contracts are verbal, month-to-month, or contain change-of-ownership termination clauses.
Confirm all federal and state licenses are current, transferable, and free of violations that could delay or block the acquisition.
Verify DEA registration is active, current, and review the full DEA inspection and audit history.
DEA violations or open investigations can prevent license transfer and halt the acquisition entirely.
Red flag: Any DEA warning letters, inspections with findings, or controlled substance discrepancy reports in the past 5 years.
Confirm state pharmacy board license is in good standing and assess change-of-ownership transfer requirements.
Most states require board approval for ownership transfer, adding 30–90 days to the closing timeline.
Red flag: State board shows active investigations, disciplinary history, or conditions attached to the current license.
Review all PBM provider agreements for change-of-ownership provisions and preferred network eligibility requirements.
PBM contracts may terminate automatically upon ownership change, eliminating reimbursement from major payers.
Red flag: One or more PBM contracts contain automatic termination clauses with no guaranteed assumption by new owner.
Request CMS, Medicaid, and Part D audit history for the past 3 years including any repayment demands.
Unresolved government payer audits can result in recoupment claims that survive an asset purchase transaction.
Red flag: Open CMS or state Medicaid audits with pending repayment demands not disclosed by the seller.
Validate inventory methodology, assess physical condition of equipment, and confirm lease terms support post-acquisition operations.
Commission an independent inventory count and confirm valuation methodology at cost, not retail pricing.
Sellers may inflate inventory value using retail prices; buyers pay replacement cost, not dispensed value.
Red flag: Seller refuses independent inventory count or cannot document inventory valuation methodology clearly.
Identify and exclude expired, controlled substance, or non-returnable inventory from the purchase price.
Expired or non-returnable drugs have zero value and should not be included in the inventory purchase price.
Red flag: Significant quantities of expired or slow-moving specialty drugs inflating the stated inventory value.
Review pharmacy equipment condition including dispensing systems, compounding hoods, and refrigeration units.
Equipment replacement costs can run $50,000–$200,000 and should be factored into purchase price negotiation.
Red flag: Core dispensing or compounding equipment is beyond useful life with no maintenance records available.
Review the facility lease for assignability, remaining term, renewal options, and landlord consent requirements.
A short lease with no renewal option creates operational risk and may limit ability to secure SBA financing.
Red flag: Lease expires within 24 months of closing with no renewal option or landlord unwilling to assign to new owner.
Assess licensed pharmacist retention, technician staffing, and operational continuity risk during the ownership transition.
Confirm all pharmacists on staff hold current state licenses and review technician certification status.
Unlicensed or lapsed staff create immediate compliance violations and operational disruption post-close.
Red flag: Key staff pharmacist licenses are expired, on probation, or subject to state board disciplinary proceedings.
Assess pharmacist retention risk by identifying whether the owner is the sole licensed pharmacist on staff.
An owner-only pharmacist model means the business cannot legally operate independently after the seller exits.
Red flag: Seller is the only licensed pharmacist and has no replacement identified or willing to stay post-close.
Review staff employment agreements, non-competes, and compensation structures for key pharmacists and technicians.
Departing staff during transition can accelerate patient attrition and disrupt prescription processing workflows.
Red flag: No employment agreements exist and key staff have received competing offers or express intent to leave.
Evaluate pharmacy management software, workflow systems, and vendor relationships for transition readiness.
Switching pharmacy management systems post-close disrupts dispensing workflow and risks patient record integrity.
Red flag: Proprietary software with no data export capability or vendor contracts that terminate upon ownership change.
Find Pharmacy Businesses For Sale
Vetted targets with diligence packages — skip the cold search.
Independent pharmacies are valued using a multiple of adjusted EBITDA, typically 3x–5.5x, plus a separate valuation of the prescription file based on active patient count and 30-day refill rates, and inventory priced at cost. Specialty or compounding capabilities, long-term care contracts, and clean compliance records all support higher multiples within that range.
PBM contracts do not automatically transfer to a new owner. Most agreements require the buyer to apply for new credentialing, and some contain change-of-ownership termination clauses that give PBMs the right to end the relationship entirely. Buyers should review every PBM agreement for these provisions before closing and begin the credentialing process as early as possible to avoid a gap in reimbursement.
The DEA does not transfer registrations — a buyer must apply for a new DEA registration, which typically takes 30–90 days depending on the state and application volume. Buyers should apply immediately upon signing a letter of intent and should not close until the new registration is approved or an interim exemption is in place, as dispensing controlled substances without a valid DEA registration is a federal violation.
The vast majority of independent pharmacy acquisitions are structured as asset purchases, where the buyer acquires the prescription file, inventory, equipment, and assumed contracts rather than the legal entity. This structure protects buyers from inheriting undisclosed liabilities such as prior DEA violations, pending PBM audits, or unresolved Medicare recoupment demands that could attach to a stock purchase of the operating entity.
More Pharmacy Guides
More Due Diligence Checklists
Stop cold-searching. Find signal-scored Pharmacy targets with seller motivation already identified.
Create your free accountNo credit card required
For Buyers
For Sellers